Trinity biotech announces the $30 million sale of its life sciences supply business to biosynth

Dublin, ireland, april 20, 2023 (globe newswire) -- trinity biotech plc (nasdaq: trib) (the “company”), a leading developer and manufacturer of diagnostic solutions for the point-of-care and clinical laboratory markets, today announced it has entered into an agreement to sell its fitzgerald industries life sciences supply business, consisting of benen trading ltd and fitzgerald industries international, inc, to biosynth for cash proceeds of approximately $30 million subject to customary adjustments. biosynth is owned, amongst others, by kkr, ampersand capital partners and management. the sale is expected to close in april 2023.
TRIB Ratings Summary
TRIB Quant Ranking